• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Platelet-derived microvesicles in thrombotic thrombocytopenic purpura and hemolytic uremic syndrome.

作者信息

Galli M, Grassi A, Barbui T

机构信息

Department of Haematology, Ospedali Riuniti, Bergamo, Italy.

出版信息

Thromb Haemost. 1996 Mar;75(3):427-31.

PMID:8701402
Abstract

Thrombotic thrombocytopenic purpura (TTP) and the related hemolytic uremic syndrome (HUS) are disorders characterized by thrombocytopenia, microangiopathic hemolytic anemia, a variable degree of impairment of renal function and fluctuating neurological symptoms, which are thought to be due to platelet activation and subsequent formation of thrombi in the microcirculation. Since platelet activation is accompanied by the generation of microvesicles (PMPs), we determined their presence in patients with TTP and HUS by flow cytometry. The analysis was performed in whole blood, using FITC-conjugated monoclonal antibodies (CD 42b and/or CD 61a). PMPs were discriminated from platelets on the basis of size and fluorescence profiles. Their levels in 21 normal controls ranged between 2.4% and 9.4% (mean +/- SD: 5.2 +/- 1.99%). No correlations were found with platelet number. PMPs were then evaluated in 13 patients with TTP and 2 cases of HUS. In all patients they were found higher than in controls, ranging from 11.0 to 91.1% (45.0 +/- 26.0%; p = 0.0001 vs controls). PMPs were serially measured in patients with TTP: at diagnosis a correlation between PMPs and platelet number was found (R]2 = 0.669) and the time-course showed that the improvement of both microangiopathy and clinical manifestations of cerebral and renal involvement was accompanied by a progressive normalization of PMP levels and platelet count. PMP levels were measured also in patients suffering from other forms of thrombocytopenia: they were 17 patients with idiopathic thrombocytopenic purpura and 10 patients with acute leukemias and severe thrombocytopenia during the aplastic phase following chemotherapy. PMP ranges were: 2.0-79.6% (21.6 +/- 20.8%; p = 0.001 vs controls) and 4.6-12.5% (8.8 +/- 2.4%; p = 0.0001 vs controls), respectively. No correlations were found between platelet number and the absolute number of PMPs in these 2 groups of patients. These findings show that increased levels of PMPs may be found in peripheral thrombocytopenias and suggest that their presence may be clinically relevant, particularly in the microangiopathic forms.

摘要

相似文献

1
Platelet-derived microvesicles in thrombotic thrombocytopenic purpura and hemolytic uremic syndrome.
Thromb Haemost. 1996 Mar;75(3):427-31.
2
Plasma von Willebrand Factor Antigen (vWF:AG) and thrombomodulin (TM) levels in Adult Thrombotic Thrombocytopenic Purpura/Hemolytic Uremic Syndromes (TTP/HUS) and bone marrow transplant-associated thrombotic microangiopathy (BMT-TM).成人血栓性血小板减少性紫癜/溶血性尿毒症综合征(TTP/HUS)及骨髓移植相关血栓性微血管病(BMT-TM)中的血浆血管性血友病因子抗原(vWF:AG)和血栓调节蛋白(TM)水平
Am J Hematol. 1996 Dec;53(4):213-20. doi: 10.1002/(SICI)1096-8652(199612)53:4<213::AID-AJH1>3.0.CO;2-0.
3
Two novel ADAMTS13 gene mutations in thrombotic thrombocytopenic purpura/hemolytic-uremic syndrome (TTP/HUS).血栓性血小板减少性紫癜/溶血性尿毒症综合征(TTP/HUS)中的两种新型ADAMTS13基因突变。
Kidney Int. 2004 Sep;66(3):955-8. doi: 10.1111/j.1523-1755.2004.00841.x.
4
Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome: the role of von Willebrand factor-cleaving protease.血栓性血小板减少性紫癜和溶血尿毒综合征的病因及发病机制:血管性血友病因子裂解蛋白酶的作用
Best Pract Res Clin Haematol. 2001 Jun;14(2):437-54. doi: 10.1053/beha.2001.0142.
5
Recent advances in thrombotic thrombocytopenic purpura.血栓性血小板减少性紫癜的最新进展
Hematology Am Soc Hematol Educ Program. 2004:407-23. doi: 10.1182/asheducation-2004.1.407.
6
Thrombotic microangiopathy in malignant hypertension and hemolytic uremic syndrome (HUS)/ thrombotic thrombocytopenic purpura (TTP): can we differentiate one from the other?恶性高血压与溶血尿毒综合征(HUS)/血栓性血小板减少性紫癜(TTP)中的血栓性微血管病:我们能将两者区分开吗?
Hypertens Res. 2005 Jan;28(1):89-95. doi: 10.1291/hypres.28.89.
7
Evaluation of Plasma Platelet Microparticles in Thrombotic Thrombocytopenic Purpura.血栓性血小板减少性紫癜中血浆血小板微粒的评估
Ann Clin Lab Sci. 2017 Jan;47(1):62-67.
8
[Microangiopathic hemolytic anemias. Clinical pattern, therapy and clinical course in 14 patients with thrombotic thrombocytopenic purpura and hemolytic uremic syndrome].[微血管病性溶血性贫血。14例血栓性血小板减少性紫癜和溶血尿毒综合征患者的临床模式、治疗及临床病程]
Schweiz Med Wochenschr. 1986 Nov 29;116(48):1666-74.
9
Increased serum levels of thrombopoietin in patients with thrombotic thrombocytopenic purpura, idiopathic thrombocytopenic purpura, or disseminated intravascular coagulation.血栓性血小板减少性紫癜、特发性血小板减少性紫癜或弥散性血管内凝血患者血清血小板生成素水平升高。
Blood Coagul Fibrinolysis. 1997 Sep;8(6):345-9. doi: 10.1097/00001721-199709000-00004.
10
Development and assessment of enzyme immunoassay for platelet-derived microparticles.血小板衍生微粒酶免疫测定法的开发与评估
Thromb Haemost. 2001 Feb;85(2):326-30.

引用本文的文献

1
The potential applications of microparticles in the diagnosis, treatment, and prognosis of lung cancer.微粒子在肺癌的诊断、治疗和预后中的潜在应用。
J Transl Med. 2022 Sep 5;20(1):404. doi: 10.1186/s12967-022-03599-x.
2
Pathophysiology of Coagulation and Emerging Roles for Extracellular Vesicles in Coagulation Cascades and Disorders.凝血的病理生理学以及细胞外囊泡在凝血级联反应和疾病中的新作用
J Clin Med. 2022 Aug 22;11(16):4932. doi: 10.3390/jcm11164932.
3
Blood Cell-Derived Microvesicles in Hematological Diseases and beyond.血液细胞衍生的微小囊泡在血液系统疾病及其他领域的作用。
Biomolecules. 2022 Jun 8;12(6):803. doi: 10.3390/biom12060803.
4
Extracellular Vesicles and Thrombosis: Update on the Clinical and Experimental Evidence.细胞外囊泡与血栓形成:临床与实验研究进展。
Int J Mol Sci. 2021 Aug 27;22(17):9317. doi: 10.3390/ijms22179317.
5
Platelet Signaling and Disease: Targeted Therapy for Thrombosis and Other Related Diseases.血小板信号转导与疾病:血栓及其他相关疾病的靶向治疗。
Pharmacol Rev. 2018 Jul;70(3):526-548. doi: 10.1124/pr.117.014530.
6
Platelet-Derived Microvesicles in Cardiovascular Diseases.心血管疾病中的血小板衍生微泡
Front Cardiovasc Med. 2017 Nov 21;4:74. doi: 10.3389/fcvm.2017.00074. eCollection 2017.
7
Extracellular vesicles and blood diseases.细胞外囊泡与血液疾病
Int J Hematol. 2017 Apr;105(4):392-405. doi: 10.1007/s12185-017-2180-x. Epub 2017 Jan 27.
8
MicroRNA-223 delivered by platelet-derived microvesicles promotes lung cancer cell invasion via targeting tumor suppressor EPB41L3.血小板衍生微泡递送的MicroRNA-223通过靶向肿瘤抑制因子EPB41L3促进肺癌细胞侵袭。
Mol Cancer. 2015 Mar 11;14:58. doi: 10.1186/s12943-015-0327-z.
9
A novel mechanism of bacterial toxin transfer within host blood cell-derived microvesicles.宿主血细胞衍生微泡内细菌毒素转移的新机制。
PLoS Pathog. 2015 Feb 26;11(2):e1004619. doi: 10.1371/journal.ppat.1004619. eCollection 2015 Feb.
10
Clinical significance of procoagulant microparticles.促凝微粒的临床意义。
J Intensive Care. 2015 Jan 7;3(1):2. doi: 10.1186/s40560-014-0066-z. eCollection 2015.